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  SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
cytidine 5 -diphosphocholine and maintenance of normal vision pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Omikron Italia S.r.l. submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to cytidine 5 -diphosphocholine and maintenance of normal vision. The Panel considers 
that the food constituent cytidine 5 -diphosphocholine (CDP-choline or citicoline), which is the subject of the 
health claim, is sufficiently characterised. The claimed effect, maintenance of normal vision, is a beneficial 
physiological effect. The Panel considers that no conclusions can be drawn from the three narrative reviews and 
the eight human intervention studies provided by the applicant for the scientific substantiation of the claim. The 
Panel concludes that a cause and effect relationship has not been established between the consumption of 
CDP-choline and maintenance of normal vision. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Omikron Italia S.r.l. submitted for authorisation of a health claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on 
the scientific substantiation of a health claim related to cytidine 5 -diphosphocholine and maintenance 
of normal vision. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food constituent that is the subject of the health claim is cytidine 5 -diphosphocholine 
(CDP-choline or citicoline). The Panel considers that the food constituent CDP-choline, which is the 
subject of the health claim, is sufficiently characterised 
The claimed effect proposed by the applicant relates to maintenance (or reduced loss) of normal 
vision. The target population proposed by the applicant is “elderly subjects since middle age”. The 
Panel considers that maintenance of normal vision is a beneficial physiological effect. 
The applicant identified eight human intervention studies, three reviews, and three non-human studies 
as being pertinent to the health claim.  
The narrative reviews referred to the pharmacological proprieties of CDP-choline, and to the 
treatment of glaucoma. Four publications reported on studies in which CDP-choline was administered 
via intramuscular injection, which is a route of administration that is not relevant to the assessment of 
health claims made on food. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
The remaining four human intervention studies investigated the effect of oral administration of 
CDP-choline on several outcome measures in subjects with glaucoma or with non-arteritic ischaemic 
optic neuropathy.  
During the evaluation process, the applicant was requested to clarify how results obtained in subjects 
with presumed damage to the retinal ganglion cells and/or optic nerve owing to glaucoma or to an 
ischaemic event could be extrapolated to the target population (i.e. healthy subjects without damaged 
retinal ganglion cells or optic nerve) for which the claim is made. The Panel notes that no evidence, 
which could justify the extrapolation of the results obtained in patients with glaucoma or with a non-
arteritic ischaemic optic neuropathy to the target population, was provided by the applicant.  
The Panel notes that no human intervention studies from which conclusions could be drawn for the 
scientific substantiation of the claim were provided by the applicant. 
The Panel considers that, in the absence of evidence of an effect of CDP-choline on the maintenance 
of normal vision in humans, the three non-human studies provided cannot be used for the scientific 
substantiation of the claim.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of CDP-choline and maintenance of normal vision. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 10/09/2013. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 The scientific evaluation procedure started on 04/10/2013. 
 On 21/11/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 02/12/2013 and was restarted on 17/12/2013, in compliance with Article 
18(3) of Regulation (EC) No 1924/2006. 
 On 18/12/2013, EFSA received the requested information (which was made available to 
EFSA in electronic format on 16/12/2013). 
 During its meeting on 05/02/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to CDP-choline 
and maintenance of normal vision.  
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: CDP-choline and maintenance of 
normal vision. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of CDP-choline, a positive assessment of its safety, nor a decision on whether CDP-choline 
is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Omikron Italia S.r.l., Viale Bruno Buozzi, 5, 00197, Rome, Italy. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006. The applicant claimed proprietary rights for the studies by 
Morreale Bubella et al. (2011) and Ottobelli et al. (2013). The applicant also claimed proprietary 
rights for information pertaining to the manufacturing process.  
Food/constituent as stated by the applicant 
According to the applicant, the health claim is made for CDP-choline in oral solution as source of 
choline as a constituent of a food supplement. Each vial of this food supplement contains 500 mg of 
CDP-choline in oral solution as source of 102 mg of choline. 
Health relationship as claimed by the applicant 
According to the applicant, CDP-choline has a positive effect on vision, helping to maintain cellular 
homeostasis of nervous structures involved in the optic pathways. By protecting the neuronal 
membranes, CDP-choline showed a secondary effect in helping physiological nervous transmission.  
In order to highlight this neuroprotective effect, particularly usable in subjects predisposed to retinal 
and post-retinal damage, it seems useful to take as a model to perform studies subjects that mimic the 
normal optical damage detectable with age but in which the damage is accelerated. For this reason, in 
order to demonstrate the substantiation of the health claim required we will make reference to studies 
on subjects with glaucoma. 
By using electrophysiological methods, it was observed that oral treatment with CDP-choline as a 
source of choline may induce enhancement of ganglion cell function (objectively evaluated by pattern 
electroretinogram recordings) and neural conduction along the post-retinal visual pathways 
(objectively evaluated by visual evoked potential recordings) leading to an improvement of visual 
function. These results, observed in subjects with glaucoma after two 60-day periods of (oral or 
intramuscular) treatment with CDP-choline, suggest its potential neuroprotective effect.  
The effects of CDP-choline on ophthalmic nervous structures were assessed through several outcome 
measures: the analysis of efficacy parameters as the slowing of visual field loss or the rebalancing of 
ophthalmological electrophysiological parameters (visual evoked potential (VEP), pattern 
electroretinogram (PERG)).  
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “CDP-choline in oral solution 
as source of choline contributes to the maintenance of normal function of the ophthalmic nervous 
structures”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is subjects predisposed to retinal and post-retinal 
damage (> 65 years old, unbalanced diet, subjects with high myopia). 
According to the applicant, the suggested daily intake is one vial for a period of four months followed 
by a two months of wash-out period. This dosage provides 500 mg of CDP-choline in oral solution 
daily as source of 102 mg of choline, which must be supplemented with a balanced diet.  
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ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is proposed by the applicant to be the subject of the health claim is 
“CDP-choline in oral solution as source of choline as constituent of a food supplement”.  
Upon a request from EFSA for clarification, the applicant indicated that the food constituent that is 
the subject of the health claim is “CDP-choline (monosodium salt) in oral solution”. 
Cytidine 5 -diphosphocholine (CDP-choline or citicoline) is a mononucleotide consisting of cytosine, 
ribose, diphosphate and choline.  
CDP-choline can be measured in foods by established methods. 
The Panel considers that the food constituent, CDP-choline, which is the subject of the health claim, 
is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant relates to maintenance (or reduced loss) of normal 
vision. The target population proposed by the applicant is “subjects predisposed to retinal and post-
retinal damage (> 65 years old, unbalanced diet, subjects with high myopia)”. 
Upon a request by EFSA for clarification, the applicant indicated that the proposed target population 
is “elderly subjects since middle age”. The Panel understands the target population to be elderly 
people in the general population.  
From the information provided, the Panel assumed that the mechanism by which CDP-choline could 
exert the claimed effect (i.e. maintenance (or reduced loss) of normal vision) is “enhancement of the 
ganglion cell function” and “neural conduction along the post-retinal visual pathways”. However, the 
Panel noted that, whereas objective measures (i.e. visual evoked potential (VEP) and pattern of 
electroretinogram (PERG)) had been proposed by the applicant to assess the mechanisms by which 
CDP-choline could exert the claimed effect, no outcome measures were proposed to evaluate the 
claimed effect (i.e. visual function) in vivo in humans. Upon a request from EFSA for clarification, 
the applicant indicated that VEP, PERG and the assessment of the visual field are outcome measures 
related to visual function.  
The Panel considers that, whereas visual field assessment is a direct outcome measure of vision, VEP 
and PERG are used to assess the integrity of cells and nerves involved in visual function but are not 
measures of vision.  
The Panel considers that maintenance of normal vision is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, without specifying the covering period, and 
using the following key words in various combinations: cytidine diphosphate choline, 
neuroprotection, visual field, pharmacokinetics, oral. Only publications in English were included.  
The applicant identified eight human intervention studies, three narrative reviews, and three non-
human studies as being pertinent to the health claim.  
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The three narrative reviews referred to the pharmacological properties of CDP-choline and to the 
treatment of glaucoma (Grieb and Rejdak, 2002; Secades, 2011; Chang and Goldberg, 2012). The 
Panel considers that no conclusions can be drawn from these references for the scientific 
substantiation of the claim. 
Four publications reported on studies in which CDP-choline was administered via intramuscular 
injection (Pecori Giraldi at al., 1989; Parisi et al., 1999, 2005; Virno et al., 2000). The Panel notes 
that parenteral routes of administration are not relevant to the assessment of health claims made on 
food and considers that these studies do not provide evidence for the scientific substantiation of a 
claim on dietary CDP-choline.  
One double-blind, placebo-controlled study by Morreale Bubella et al. (2011), one open-label 
randomised controlled study (Parisi et al., 2008) and two uncontrolled (single arm) studies (Rejdak et 
al., 2003; Ottobelli et al., 2013) investigated the effect of oral administration of CDP-choline on 
several outcome measures which included VEP, PERG, visual acuity and visual field in subjects with 
glaucoma (Rejdak et al., 2003; Morreale Bubella et al., 2011; Ottobelli at al., 2013) or with non-
arteritic ischaemic optic neuropathy (Parisi et al., 2008).  
During the evaluation process, the applicant was requested to clarify how results obtained in subjects 
with presumed damage to the retinal ganglion cells and/or the optic nerve owing to glaucoma or to an 
ischaemic event could be extrapolated to the target population (i.e. healthy subjects without damaged 
retinal ganglion cells and optic nerve) for which the claim is made. In reply the applicant provided 
two studies: one study described a method for PERG recording in healthy subjects, of different ages, 
with the purpose of providing normative data for screening and follow-up of glaucoma (Porciatti and 
Ventura, 2004); the second study investigated how PERG (latency and amplitude) in patients with 
glaucoma can be reproduced in subjects without glaucoma by amending the conditions of the test 
(Porciatti and Ventura, 2009). The Panel notes that these studies do not provide evidence which could 
justify the extrapolation of the results obtained in patients with glaucoma or with a non-arteritic 
ischaemic optic neuropathy to the target population. The Panel considers that no conclusions can be 
drawn from these studies for the scientific substantiation of the claim. 
The Panel notes that no human intervention studies from which conclusions could be drawn for the 
scientific substantiation of the claim were provided by the applicant. 
The applicant also provided one in vitro and two animal studies on the effect of CDP-choline on the 
regeneration of neuritis in mouse retina culture (Oshitari et al., 2002), on concentration of 
neurotransmitters in retina in rabbits (Rejdak et al. (2002) or on serum CDP-choline concentrations in 
rats following different routes of administration (Roda et al. 1983). The Panel considers that, in the 
absence of evidence of an effect of CDP-choline on the maintenance of normal vision in humans, non-
human studies cannot be used for the scientific substantiation of the claim.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of CDP-choline and maintenance of normal vision. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent CDP-choline, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect proposed by the applicant relates to maintenance (or reduced loss) of 
normal vision. The target population proposed by the applicant is “elderly subjects since 
middle age”. Maintenance of normal vision is a beneficial physiological effect. 
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 A cause and effect relationship has not been established between the consumption of 
CDP-choline and maintenance of normal vision. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on CDP-choline and maintenance of normal vision pursuant to Article 13(5) 
of Regulation (EC) No 1924/2006 (Claim serial No: 0396_IT). September 2013. Submitted by 
Omikron Italia S.r.l. 
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ABBREVIATIONS 
CDP-choline  Cytidine 5 -diphosphocholine 
PERG   Pattern of electroretinogram 
VEP   Visual evoked potential 
 
